Market Research Life Sciences Market Research Medical Devices Market Research Infusion Products Market Research

Australia Diabetes Market, Size, Forecast 2023-2028, By SMBG Device, Continuous Glucose Monitoring (CGM), Insulin Pen, Insulin Pump, and Company Analysis

Best Price Guarantee Length Publisher Published Date SKU
from $2,990 190 Pages Renub Research March, 2023 RNBR17831883
Best Price Guarantee
Price from $2,990
Length 190 Pages
Publisher Renub Research
Published Date March, 2023
SKU RNBR17831883

Australia Diabetes Market, Size, Forecast 2023-2028, By SMBG Device, Continuous Glucose Monitoring (CGM), Insulin Pen, Insulin Pump, and Company Analysis

Australia Diabetes Market will reach US$ 5.96 Billion in 2028 and it will expand at a CAGR of 7.14% from 2022 to 2028, according to Renub Research. In recent years, Australia diabetes has been on the rise. The diabetes burden in Australia shows no sign of slowing, and its health and economic impact continue to be felt by people with diabetes. Almost 1.9 million Australians have diabetes and it is the seventh most common cause of death by disease. Australia is home to an aging population and the Australian Government, like other governments worldwide, faces the challenge of dealing with the issue of rising healthcare costs. Obesity is an increasingly serious issue for Australia. The number of people with type 2 diabetes is growing, most likely the result of rising overweight and obesity rates, lifestyle and dietary changes, and an ageing population. Australia Diabetes Market was US$ 3.94 Billion in 2022.

Type 2 Diabetes is Increasing Year on Year

The number of people living with diabetes in Australia increased almost 2.8-fold between 2000 and 2020. Currently, 134 thousand Australians are living with type 1 diabetes. Type 1 diabetes is usually confirmed with an extra blood test to check autoantibodies. However, type 2 diabetes is increasing at the fastest rate in Australia. Type 2 diabetes is one of the significant consequences of the modern lifestyle. In addition, the number of people with silent, undiagnosed type 2 diabetes may be damaging their bodies. An estimated 2 million Australians are at high risk of developing type 2 diabetes and are already showing early signs of the condition.

Growing Number of Diabetes cases in Australia will create demand for Insulin Pens

The Australian diabetes market is classified into Self-Monitoring Blood Glucose Devices, Continuous Glucose Monitoring (CGM) Devices, Insulin pens, and Insulin Pumps. The growing adoption of insulin-delivery devices and the rising prevalence of diabetes are driving market growth. Therefore, leading Australian manufacturers are focusing on technological innovations and developing advanced products to gain a substantial market share. The rapidly increasing incidence and prevalence of diabetic patients and healthcare expenditure in Australia are indications of the increasing usage of diabetic care products.

After Insulin Pens, CGMs accounted for the largest share of the Australian diabetes market. Increasing adoption of CGM systems, development of advanced CGM systems, favorable government policies, and promotion of the adoption of CGM devices are the key factors contributing to this segment capturing maximum share and highest growth.

Australian Government has developed a National Diabetes Strategy

The government plays a significant role in assuring that people with diabetes can access affordable, high-quality equipment and services to help in self-management and care. The National Diabetes Services Plan, the Prescription Benefits Scheme, the Insulin Pump Program, and Medicare are all initiatives the Australian government administers to assist people with diabetes.

More than 3.1 million Australians will live with diabetes by 2050; around one in every 12 Australians, According to Diabetes Australia administers the National Diabetes Services Scheme (NDSS). Direct healthcare, hospital costs, and medicines have exploded in the past two decades, while hospitalizations have increased since 2004. The diabetes epidemic is one of the most significant health challenges Australia has ever faced, and it calls for unified and sustained action.

Key Players Analysis

The major players are B. Braun Melsungen AG, Eli Lilly and Company, Terumo Corporation, Becton, Dickinson (BD), Novo Nardisk, Ypsomed AG, Medtronic, Insulet Corporations, Abbott Laboratories, DarioHealth Crop, Dexcom, Inc, Roche Diagnostic, Tandem Diabetes Care.

In January 2021, the National Diabetes Services Scheme (NDSS) Australia approved using the Dexcom G6 CGM device through the NDSS Subsidy Initiative if diabetes patients use a Tandem t: slim X2 insulin pump and meet the NDSS criteria.
In Feb 2020, the Australian government initiated USD 300 Million CGM (Continuous Glucose Monitoring) (FreeStyleLibre flash glucose monitoring system) free access to eligible type-1 diabetes patients.

Renub Research report titled “AustraliaDiabetes Market & Forecast, By Continuous Glucose Monitoring (CGM Market by Components, Glucose Sensor, Transmitter, CGM User, Reimbursement), Self-Monitoring Blood Glucose Device Analysis (SMBG Market by, Test Strips, Lancet, Meter, Blood Glucose Device Users & Reimbursement) Insulin Pen Analysis – (User, Types – Disposable, Reusable and Smart Insulin Pen, Insulin Pen Needle Market, Reimbursement Policies), Insulin Pump Analysis- (Users, Market & Differentiation Points of Insulin Pump Products, Training Model for Patients & HCP, Reimbursement Policies) Companies (B. Braun Melsungen AG, Eli Lilly and Company, Terumo Corporation, Becton, Dickinson (BD), Novo Nardisk, Ypsomed AG, Medtronic, Insulet Cororation, Abbott Laboratories, DarioHealth Crop, Dexcom, Inc, Roche Diagnostic, Tandem Diabetes Care)” provides a complete analysis of Australia Insulin Delivery Devices Market.

Segments Market based on Devices

1. Continuous Glucose Monitoring (CGM)
2. Self Monitoring Blood Glucose (SMBG)
3. Insulin Pen
4. Insulin Pump

Australia Diabetes Sub-Segment Analysis

1. Continuous Glucose Monitoring (CGM)
1. Glucose Sensor Market & Forecast
2. CGM Transmitter Market & Forecast
3. CGM User
4. CGM Reimbursement

2. SMBG

1. Test Strips Market and Forecast
2. Lancet Market and Forecast
3. Meter Market and Forecast
4. Blood Glucose (SMBG) Users
5. Blood Glucose Devices Reimbursement

3. Insulin Pen Market

1. Disposable Insulin Pen
2. Reusable Insulin Pen
3. Smart Insulin Pen
4. Insulin Pen Needle Market
5. Insulin Pen Users
6. Reimbursement Policies

4. Insulin Pump Market

1. Insulin Pump Market
2. Insulin Pump Users
3. Insulin Pump Products
4. Reimbursement Policies

All the 13 Companies Studied in the Report have been Studied from 3 Points

• Company Overview
• Recent Developments
• Financial Insight

Company Analysis

1. B. Braun Melsungen AG
2. Eli Lilly and Company
3. Terumo Corporation
4. Becton, Dickinson (BD)
5. Novo Nardisk
6. Ypsomed AG
7. Medtronic
8. InsuletCororation
9. Abbott Laboratories
10. DarioHealth Crop
11. Dexcom, Inc
12. Roche Diagnostic
13. Tandem Diabetes Care


1. Introduction
2. Research & Methodology
3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. Australia Diabetes Market
6. Australia Diabetes Population
6.1 Type 1 Diabetes
6.2 Type 2 Diabetes
7. Market Share – Australia Diabetes Analysis
7.1 By Types
8. Continuous Glucose Monitoring Market (CGM) – Market & Users
8.1 CGM Market by Components
8.1.1 Glucose Sensor Market
8.1.2 CGM Transmitter Market
8.2 CGM User
8.3 Reimbursement Policies of CGM Devices in Australia
9. Blood Glucose Device (SMBG) – Australia Market & Users
9.1 Market
9.1.1 Type 1 Diabetes Market
9.1.2 Type 2 Diabetes Market
9.2 Test Strips Market
9.2.1 Type 1 Diabetes
9.2.2 Type 2 Diabetes
9.3 Lancet Market
9.3.1 Type 1 Diabetes
9.3.2 Type 2 Diabetes
9.4 Meter Market and Forecast
9.4.1 Type 1 Diabetes
9.4.2 Type 2 Diabetes
9.5 Blood Glucose (SMBG) Users
9.5.1 Type 1 Diabetes
9.5.2 Type 2 Diabetes
9.6 Reimbursement Policies of Blood Glucose Devices in Australia
10. Insulin Pen – Australia Market & User Analysis
10.1 Insulin Pen Market
10.1.1 Disposable Insulin Pen Market
10.1.2 Reusable Insulin Pen Market
10.1.3 Smart Insulin Pen Market
10.2 Insulin Pen User
10.2.1 Disposable Insulin Pen User
10.2.2 Reusable Insulin Pen User
10.2.3 Smart Insulin Pen User
10.3 Insulin Pen Needle Market
10.4 Reimbursement Policies of Insulin Pen in Australia
11. Insulin Pump – Australia Market & Users
11.1 Insulin Pump Market
11.1.1 Type 1 Diabetes Market
11.1.2 Type 2 Diabetes Market
11.2 Insulin Pump User
11.2.1 Type 1 Insulin Pump User
11.2.2 Type 2 Insulin Pump User
11.3 Differentiation Points of Insulin Pump Products in Australia
11.3.1 Animas Vibe
11.3.2 Medtronic 530G with Enlite
11.3.3 Insulet OmniPod
11.3.4 Tandem t: slim
11.3.5 Roche Accu-Chek Combo
11.4 Training Model for Patients & HCP – of Medtronic, Animas, Insulet Corp & Tandem Diabetes Care
11.4.1 Medtronic
11.5 Insulet Corporation
11.5.1 Training Structure for New Patients - Insulet Corporation
11.6 Animas Corporation
11.6.1 Training Modules for New Patients
11.6.2 Training Modules for HCP (Health Care Professional)
11.7 Tandem Diabetes Care
11.8 Reimbursement Policies Insulin Pump
12. Insulin Pen – Company Analysis
12.1 B. Braun Melsungen AG
12.1.1 Overview
12.1.2 Recent Developments
12.1.3 Revenue
12.2 Eli Lilly
12.2.1 Overview
12.2.2 Recent Developments
12.2.3 Revenue
12.3 Terumo Corporation
12.3.1 Overview
12.3.2 Recent Developments
12.3.3 Revenue
12.4 BD
12.4.1 Overview
12.4.2 Recent Developments
12.4.3 Revenue
12.5 Novo Nordisk A/S
12.5.1 Overview
12.5.2 Recent Developments
12.5.3 Revenue
12.6 Ypsomed AG
12.6.1 Overview
12.6.2 Recent Developments
12.6.3 Revenue
13. Insulin Pump – Company Analysis
13.1 Medtronic
13.1.1 Overview
13.1.2 Recent Developments
13.1.3 Revenue
13.2 Insulet Corporation
13.2.1 Overview
13.2.2 Recent Developments
13.2.3 Revenue
14. SMBG – Company Analysis
14.1 LifeScan Inc.
14.1.1 Overview
14.1.2 Recent Developments
14.1.3 Revenue
14.2 Abbott Laboratories
14.2.1 Overview
14.2.2 Recent Developments
14.2.3 Revenue
15. CGM – Company Analysis
15.1 Dexcom Inc
15.1.1 Overview
15.1.2 Recent Developments
15.1.3 Revenue
15.2 Roche
15.2.1 Overview
15.2.2 Recent Developments
15.2.3 Revenue
15.3 Tandem Diabetes Care
15.3.1 Overview
15.3.2 Recent Developments
15.3.3 Revenue
List of Figures:
Figure-01: Australia – Diabetes Market (Billion US$), 2017 – 2022
Figure-02: Australia – Forecast for Diabetes Market (Billion US$), 2023 – 2028
Figure-03: Australia – Type 1 Diabetes Population (Thousand), 2017 – 2022
Figure-04: Australia – Forecast for Type 1 Diabetes Population (Thousand), 2023 – 2028
Figure-05: Australia – Type 2 Diabetes Population (Thousand), 2017 – 2022
Figure-06: Australia – Forecast for Type 2 Diabetes Population (Thousand), 2023 – 2028
Figure-07: Australia – Glucose Sensor Market (Million US$), 2017 – 2023
Figure-08: Australia – Forecast for Glucose Sensor Market (Million US$), 2023 – 2028
Figure-09: Australia – CGM Transmitter Market (Million US$), 2017 – 2023
Figure-10: Australia – Forecast for CGM Transmitter Market (Million US$), 2023 – 2028
Figure-11: Australia – CGM User (Thousand), 2017 – 2023
Figure-12: Australia – Forecast for CGM User (Thousand), 2023 – 2028
Figure-13: Australia – Self-Monitoring of Blood Glucose (SMBG) Type 1 Diabetes Market (Million US$), 2023 – 2028
Figure-14: Australia – Forecast for Self-Monitoring of Blood Glucose (SMBG) Type 1 Diabetes Market (Million US$), 2017 – 2023
Figure-15: Australia – Self-Monitoring of Blood Glucose (SMBG) Type 2 Diabetes Market (Million US$), 2023 – 2028
Figure-16: Australia – Forecast for Self-Monitoring of Blood Glucose (SMBG) Type 2 Diabetes Market (Million US$), 2017 – 2023
Figure-17: Australia – Test Strips Type 1 Diabetes Market (Million US$), 2023 – 2028
Figure-18: Australia – Forecast for Test Strips Type 1 Diabetes Market (Million US$), 2017 – 2023
Figure-19: Australia – Test Strips Type 2 Diabetes Market (Million US$), 2023 – 2028
Figure-20: Australia – Forecast for Test Strips Type 2 Diabetes Market (Million US$), 2017 – 2023
Figure-21: Australia – Lancet Type 1 Diabetes Market (Million US$), 2023 – 2028
Figure-22: Australia – Forecast for Lancet Type 1 Diabetes Market (Million US$), 2017 – 2023
Figure-23: Australia – Lancet Type 2 Diabetes Market (Million US$), 2023 – 2028
Figure-24: Australia – Forecast for Lancet Type 2 Diabetes Market (Million US$), 2017 – 2023
Figure-25: Australia – Meter Type 1 Diabetes Market (Million US$), 2023 – 2028
Figure-26: Australia – Forecast for Meter Type 1 Diabetes Market (Million US$), 2017 – 2023
Figure-27: Australia – Meter Type 2 Diabetes Market (Million US$), 2023 – 2028
Figure-28: Australia – Forecast for Meter Type 2 Diabetes Market (Million US$), 2017 – 2023
Figure-29: Australia – Self-Monitoring of Blood Glucose (SMBG) Type 1 Users (Thousand), 2017 – 2022
Figure-30: Australia – Forecast for Self-Monitoring of Blood Glucose (SMBG) Type 1 Users (Thousand), 2023 – 2028
Figure-31: Australia – Self-Monitoring of Blood Glucose (SMBG) Type 2 Users (Thousand), 2017 – 2022
Figure-32: Australia – Forecast for Self-Monitoring of Blood Glucose (SMBG) Type 2 Users (Thousand), 2023 – 2028
Figure-33: Australia – Disposable Insulin Pen Market (Million US$), 2017 – 2023
Figure-34: Australia – Forecast for Disposable Insulin Pen Market (Million US$), 2023 – 2028
Figure-35: Australia – Reusable Insulin Pen Market (Million US$), 2017 – 2023
Figure-36: Australia – Forecast for Reusable Insulin Pen Market (Million US$), 2023 – 2028
Figure-37: Australia – Smart Insulin Pen Market (Million US$), 2017 – 2023
Figure-38: Australia – Forecast for Smart Insulin Pen Market (Million US$), 2023 – 2028
Figure-39: Australia – Disposable Insulin Pen User (Thousand), 2017 – 2022
Figure-40: Australia – Forecast for Disposable Insulin Pen User (Thousand), 2023 – 2028
Figure-41: Australia – Reusable Insulin Pen User (Thousand), 2017 – 2022
Figure-42: Australia – Forecast for Reusable Insulin Pen User (Thousand), 2023 – 2028
Figure-43: Australia – Smart Insulin Pen User (Thousand), 2017 – 2022
Figure-44: Australia – Forecast for Smart Insulin Pen User (Thousand), 2023 – 2028
Figure-45: Australia – Insulin Pen Needle Market (Million US$), 2017 – 2023
Figure-46: Australia – Forecast for Pen Needle Market (Million US$), 2023 – 2028
Figure-47: Australia – Insulin Pump Market for Type 1 Diabetes Market (Million US$), 2017 – 2023
Figure-48: Australia – Forecast for Insulin Pump Market for Type 1 Diabetes Market (Million US$), 2023 – 2028
Figure-49: Australia – Insulin Pump Market for Type 2 Diabetes Market (Million US$), 2017 – 2023
Figure-50: Australia – Forecast for Insulin Pump Market for Type 2 Diabetes Market (Million US$), 2023 – 2028
Figure-51: Australia – Insulin Pump Type 1 Users (Thousand), 2017 – 2022
Figure-52: Australia – Forecast for Insulin Pump Type 1 Users (Thousand), 2023 – 2028
Figure-53: Australia – Insulin Pump Type 2 Users (Thousand), 2017 – 2022
Figure-54: Australia – Forecast for Insulin Pump Type 2 Users (Thousand), 2023 – 2028
Figure-55: B. Braun Melsungen AG – Global Revenue (Billion US$), 2017 – 2022
Figure-56: B. Braun Melsungen AG – Forecast for Global Revenue (Billion US$), 2023 – 2028
Figure-57: Eli Lilly – Global Revenue (Million US$), 2017 – 2022
Figure-58: Eli Lilly – Forecast for Global Revenue (Million US$), 2023 – 2028
Figure-59: Terumo Corporation – Global Revenue (Billion US$), 2017 – 2022
Figure-60: Terumo Corporation – Forecast for Global Revenue (Billion US$), 2023 – 2028
Figure-61: BD – Global Revenue (Billion US$), 2017 – 2022
Figure-62: BD – Forecast for Global Revenue (Billion US$), 2023 – 2028
Figure-63: Novo Nordisk A/S – Global Revenue (Million US$), 2017 – 2022
Figure-64: Novo Nordisk A/S – Forecast for Global Revenue (Million US$), 2023 – 2028
Figure-65: Ypsomed AG – Global Revenue (Million US$), 2017 – 2022
Figure-66: Ypsomed AG – Forecast for Global Revenue (Million US$), 2023 – 2028
Figure-67: Medtronic – Global Revenue (Billion US$), 2017 – 2022
Figure-68: Medtronic – Forecast for Global Revenue (Billion US$), 2023 – 2028
Figure-69: Insulet Corporation – Global Revenue (Million US$), 2017 – 2022
Figure-70: Insulet Corporation – Forecast for Global Revenue (Million US$), 2023 – 2028
Figure-71: DarioHealth Corp – Global Revenue (Million US$), 2017 – 2022
Figure-72: DarioHealth Corp – Forecast for Global Revenue (Million US$), 2023 – 2028
Figure-73: Abbott Laboratories – Global Revenue (Billion US$), 2017 – 2022
Figure-74: Abbott Laboratories – Forecast for Global Revenue (Billion US$), 2023 – 2028
Figure-75: Dexcom Inc – Global Revenue (Billion US$), 2017 – 2022
Figure-76: Dexcom Inc – Forecast for Global Revenue (Billion US$), 2023 – 2028
Figure-77: Roche – Global Revenue (Billion US$), 2017 – 2022
Figure-78: Roche – Forecast for Global Revenue (Billion US$), 2023 – 2028
Figure-79: Tandem Diabetes Care – Global Revenue (Million US$), 2017 – 2022
Figure-80: Tandem Diabetes Care – Forecast for Global Revenue (Million US$), 2023 – 2028
List of Tables:
Table-01: Australia – Diabetes Market Share by Type (Percent), 2017 – 2022
Table-02: Australia – Forecast for Diabetes Market Share by Type (Percent), 2023 – 2028

$2,990
$3,990

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings